Physician profile
Bruce D Richman
NPI 1609927441
$19,215.22
in general payments reported to CMS, 2019-2025
66 companies · $3,395 in 2025
The $3,395 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $2,112 · 2021: $2,706 · 2022: $3,469 · 2023: $2,522 · 2024: $2,924 · 2025: $3,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,801 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,801.29 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,041.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,609.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,303.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,031.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $702.10 | 2019-2025 | Qelbree, Qelbree |
| Corcept Therapeutics | $670.40 | 2019-2023 | Korlym |
| Gilead Sciences, INC. | $585.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $484.05 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $451.91 | 2022-2025 | |
| Astellas Pharma US INC | $438.10 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.38 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $387.24 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $381.63 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.26 | 2024-2025 | Caplyta |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Richman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.